May 04, 2021 / 08:20PM GMT
Asthika Goonewardene - Truist Securities, Inc., Research Division - Research Analyst
All right. So, let me welcome everyone to the final panel session today for -- the company presentation session today for the Truist Securities Life Sciences Summit. I'm really pleased to have IGM Biosciences up next, and from IGM Bio, we have Fred Schwarzer, CEO.
Before we start off, let me read out some quick disclosures. This call is arranged by Truist Securities Research for use by institutional investors and issuer clients as defined by FINRA. If you are not an institutional investor or issuer, please disconnect at this time. For required disclosures, please see our website, truistsecurities.com, or our equity research library.
Fred, welcome.
Fred Schwarzer - IGM Biosciences, Inc. - CEO
Well, thank you. I really appreciate it. I guess I better make my own forward-looking statement disclosure to say that we may talk about things in the future and you should -- you know, things may not always turn out the way we hope and so you should probably read the risk
IGM Biosciences Inc at Truist Securities Life Sciences Summit (May Series) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot